Pineoblastoma segregates into molecular sub-groups with distinct clinico-pathologic features: a Rare Brain Tumor Consortium registry study

Pineoblastomas (PBs) are rare, aggressive pediatric brain tumors of the pineal gland with modest overall survival despite intensive therapy. We sought to define the clinical and molecular spectra of PB to inform new treatment approaches for this orphan cancer. Tumor, blood, and clinical data from 91 patients with PB or supratentorial primitive neuroectodermal tumor (sPNETs/CNS-PNETs), and 2 pineal parenchymal tumors of intermediate differentiation (PPTIDs) were collected from 29 centres in the Rare Brain Tumor Consortium. We used global DNA methylation profiling to define a core group of PB from 72/93 cases, which were delineated into five molecular sub-groups. Copy number, whole exome and targeted sequencing, and miRNA expression analyses were used to evaluate the clinico-pathologic significance of each sub-group. Tumors designated as group 1 and 2 almost exclusively exhibited deleterious homozygous loss-of-function alterations in miRNA biogenesis genes (DICER1, DROSHA, and DGCR8) in 62 and 100% of group 1 and 2 tumors, respectively. Recurrent alterations of the oncogenic MYC-miR-17/92-RB1 pathway were observed in the RB and MYC sub-group, respectively, characterized by RB1 loss with gain of miR-17/92, and recurrent gain or amplification of MYC. PB sub-groups exhibited distinct clinical features: group 1–3 arose in older children (median ages 5.2–14.0 years) and had intermediate to excellent survival (5-year OS of 68.0–100%), while Group RB and MYC PB patients were much younger (median age 1.3–1.4 years) with dismal survival (5-year OS 37.5% and 28.6%, respectively). We identified age

Prolifération cellulaire et protéine HuR dans les méningiomes

Accès restreint aux membres de l'Université de Lorraine jusqu'au 2015-04-01Introduction and objectives: Meningiomas are frequent and in most of cases low grade intracranial tumors, with frequent recurrences. The first objective of this study was to evaluate the prognostic value of proliferation and cell cycle markers in a series of 60 meningiomas. HuR (ELAV-like 1) is a pro-oncogenic protein that stimulates cell proliferation and survival. In the second part of this study, the objective was to evaluate HuR expression, and the effects of HuR inhibition on proliferation, apoptosis and resistance to hypoxia. Results: We found a significant correlation between histological grade and nuclear staining for MCM6 (p<0.001), Ki-67 (p<0.001) and PHH3 (p<0.001), and an inverse correlation between these markers and reccurence free survival (Cox; MCM6: p<0.001; Ki-67: p=0.003; PHH3: p=0.037). Cytoplasm staining for HuR was significantly stronger in atypical meningiomas (grades I vs II: p=0.0007), inversely correlated with progression free survival (p=0.028), and was positively correlated with mitotic index (p=0.0001), Ki-67 (p=0.0007) and MCM6 (p=0.0009). In vitro, HuR inhibition (siRNA) led to a significant decrease of cell growth (p=0.0004) and proliferation (Ki-67, p=0.0004), and an increase of apoptosis (cleaved caspase 3, p=0.002). These effects were significantly increased under hypoxia, comparing with normoxia. When HuR was inhibited, SIRT1 was decreased, both under normoxia (p=0.01) and hypoxia (p=0.0006). Conclusion: In conclusion, MCM6 is an efficient marker to identify meningiomas with high risk of recurrence. HuR is correlated with a poor prognosis. Its inhibition allows to decrease cell proliferation and to increase apoptosisIntroduction et objectifs : Les méningiomes sont des tumeurs intracrâniennes pour la plupart de bas grade, dont les récidives sont cependant fréquentes. Le premier objectif de cette étude est d'évaluer la valeur pronostique de marqueurs de prolifération dans une série de 60 méningiomes. HuR (ELAV-like 1) est une protéine pro-oncogène pouvant stimuler la prolifération et la survie cellulaire. Dans la seconde partie de cette étude, nous analysons l'expression de HuR et les effets de l'inhibition de HuR sur la prolifération, l'apoptose et la résistance à l'hypoxie. Résultats : Il existe une corrélation significative entre le grade histologique et l'expression nucléaire de MCM6 (p<0,001), Ki-67 (p<0,001) et PHH3 (p<0,001), et une corrélation inverse entre ces marqueurs et la survie sans récidive (Cox ; MCM6 : p<0,001 ; Ki-67 : p=0,003 ; PHH3 : p=0,037). L'expression cytoplasmique de HuR est corrélée négativement avec la survie sans récidive (p=0,028), et positivement avec le grade (I vs II : p=0,0007), l'indice mitotique (p=0,0001), Ki-67 (p=0,0007) et MCM6 (p=0,0009). In vitro, l'inhibition de HuR (siRNA) entraîne une diminution de la croissance cellulaire (p=0,0004) et de la prolifération (Ki-67, p=0,0004), et une augmentation de l'apoptose (caspase 3 clivée, p=0,002), ces différents effets étant significativement augmentés en hypoxie. L'inhibition de HuR entraîne également une diminution de SIRT1 en normoxie (p=0,01) et en hypoxie (p=0,0006). Conclusion : MCM6 est un marqueur efficace pour identifier les méningiomes à haut risque de récidive. HuR est un marqueur de mauvais pronostic, dont l'inhibition permet de diminuer la prolifération cellulaire et d'augmenter l'apoptos

Cell proliferation and Hur protein in meningiomas

Introduction et objectifs : Les méningiomes sont des tumeurs intracrâniennes pour la plupart de bas grade, dont les récidives sont cependant fréquentes. Le premier objectif de cette étude est d'évaluer la valeur pronostique de marqueurs de prolifération dans une série de 60 méningiomes. HuR (ELAV-like 1) est une protéine pro-oncogène pouvant stimuler la prolifération et la survie cellulaire. Dans la seconde partie de cette étude, nous analysons l'expression de HuR et les effets de l'inhibition de HuR sur la prolifération, l'apoptose et la résistance à l'hypoxie. Résultats : Il existe une corrélation significative entre le grade histologique et l'expression nucléaire de MCM6 (p<0,001), Ki-67 (p<0,001) et PHH3 (p<0,001), et une corrélation inverse entre ces marqueurs et la survie sans récidive (Cox ; MCM6 : p<0,001 ; Ki-67 : p=0,003 ; PHH3 : p=0,037). L'expression cytoplasmique de HuR est corrélée négativement avec la survie sans récidive (p=0,028), et positivement avec le grade (I vs II : p=0,0007), l'indice mitotique (p=0,0001), Ki-67 (p=0,0007) et MCM6 (p=0,0009). In vitro, l'inhibition de HuR (siRNA) entraîne une diminution de la croissance cellulaire (p=0,0004) et de la prolifération (Ki-67, p=0,0004), et une augmentation de l'apoptose (caspase 3 clivée, p=0,002), ces différents effets étant significativement augmentés en hypoxie. L'inhibition de HuR entraîne également une diminution de SIRT1 en normoxie (p=0,01) et en hypoxie (p=0,0006). Conclusion : MCM6 est un marqueur efficace pour identifier les méningiomes à haut risque de récidive. HuR est un marqueur de mauvais pronostic, dont l'inhibition permet de diminuer la prolifération cellulaire et d'augmenter l'apoptoseIntroduction and objectives: Meningiomas are frequent and in most of cases low grade intracranial tumors, with frequent recurrences. The first objective of this study was to evaluate the prognostic value of proliferation and cell cycle markers in a series of 60 meningiomas. HuR (ELAV-like 1) is a pro-oncogenic protein that stimulates cell proliferation and survival. In the second part of this study, the objective was to evaluate HuR expression, and the effects of HuR inhibition on proliferation, apoptosis and resistance to hypoxia. Results: We found a significant correlation between histological grade and nuclear staining for MCM6 (p<0.001), Ki-67 (p<0.001) and PHH3 (p<0.001), and an inverse correlation between these markers and reccurence free survival (Cox; MCM6: p<0.001; Ki-67: p=0.003; PHH3: p=0.037). Cytoplasm staining for HuR was significantly stronger in atypical meningiomas (grades I vs II: p=0.0007), inversely correlated with progression free survival (p=0.028), and was positively correlated with mitotic index (p=0.0001), Ki-67 (p=0.0007) and MCM6 (p=0.0009). In vitro, HuR inhibition (siRNA) led to a significant decrease of cell growth (p=0.0004) and proliferation (Ki-67, p=0.0004), and an increase of apoptosis (cleaved caspase 3, p=0.002). These effects were significantly increased under hypoxia, comparing with normoxia. When HuR was inhibited, SIRT1 was decreased, both under normoxia (p=0.01) and hypoxia (p=0.0006). Conclusion: In conclusion, MCM6 is an efficient marker to identify meningiomas with high risk of recurrence. HuR is correlated with a poor prognosis. Its inhibition allows to decrease cell proliferation and to increase apoptosi

Prolifération cellulaire et protéine HuR dans les méningiomes

Accès restreint aux membres de l'Université de Lorraine jusqu'au 2015-04-01Introduction and objectives: Meningiomas are frequent and in most of cases low grade intracranial tumors, with frequent recurrences. The first objective of this study was to evaluate the prognostic value of proliferation and cell cycle markers in a series of 60 meningiomas. HuR (ELAV-like 1) is a pro-oncogenic protein that stimulates cell proliferation and survival. In the second part of this study, the objective was to evaluate HuR expression, and the effects of HuR inhibition on proliferation, apoptosis and resistance to hypoxia. Results: We found a significant correlation between histological grade and nuclear staining for MCM6 (p<0.001), Ki-67 (p<0.001) and PHH3 (p<0.001), and an inverse correlation between these markers and reccurence free survival (Cox; MCM6: p<0.001; Ki-67: p=0.003; PHH3: p=0.037). Cytoplasm staining for HuR was significantly stronger in atypical meningiomas (grades I vs II: p=0.0007), inversely correlated with progression free survival (p=0.028), and was positively correlated with mitotic index (p=0.0001), Ki-67 (p=0.0007) and MCM6 (p=0.0009). In vitro, HuR inhibition (siRNA) led to a significant decrease of cell growth (p=0.0004) and proliferation (Ki-67, p=0.0004), and an increase of apoptosis (cleaved caspase 3, p=0.002). These effects were significantly increased under hypoxia, comparing with normoxia. When HuR was inhibited, SIRT1 was decreased, both under normoxia (p=0.01) and hypoxia (p=0.0006). Conclusion: In conclusion, MCM6 is an efficient marker to identify meningiomas with high risk of recurrence. HuR is correlated with a poor prognosis. Its inhibition allows to decrease cell proliferation and to increase apoptosisIntroduction et objectifs : Les méningiomes sont des tumeurs intracrâniennes pour la plupart de bas grade, dont les récidives sont cependant fréquentes. Le premier objectif de cette étude est d'évaluer la valeur pronostique de marqueurs de prolifération dans une série de 60 méningiomes. HuR (ELAV-like 1) est une protéine pro-oncogène pouvant stimuler la prolifération et la survie cellulaire. Dans la seconde partie de cette étude, nous analysons l'expression de HuR et les effets de l'inhibition de HuR sur la prolifération, l'apoptose et la résistance à l'hypoxie. Résultats : Il existe une corrélation significative entre le grade histologique et l'expression nucléaire de MCM6 (p<0,001), Ki-67 (p<0,001) et PHH3 (p<0,001), et une corrélation inverse entre ces marqueurs et la survie sans récidive (Cox ; MCM6 : p<0,001 ; Ki-67 : p=0,003 ; PHH3 : p=0,037). L'expression cytoplasmique de HuR est corrélée négativement avec la survie sans récidive (p=0,028), et positivement avec le grade (I vs II : p=0,0007), l'indice mitotique (p=0,0001), Ki-67 (p=0,0007) et MCM6 (p=0,0009). In vitro, l'inhibition de HuR (siRNA) entraîne une diminution de la croissance cellulaire (p=0,0004) et de la prolifération (Ki-67, p=0,0004), et une augmentation de l'apoptose (caspase 3 clivée, p=0,002), ces différents effets étant significativement augmentés en hypoxie. L'inhibition de HuR entraîne également une diminution de SIRT1 en normoxie (p=0,01) et en hypoxie (p=0,0006). Conclusion : MCM6 est un marqueur efficace pour identifier les méningiomes à haut risque de récidive. HuR est un marqueur de mauvais pronostic, dont l'inhibition permet de diminuer la prolifération cellulaire et d'augmenter l'apoptos

Prolifération cellulaire et protéine HuR dans les méningiomes

Introduction et objectifs : Les méningiomes sont des tumeurs intracrâniennes pour la plupart de bas grade, dont les récidives sont cependant fréquentes. Le premier objectif de cette étude est d'évaluer la valeur pronostique de marqueurs de prolifération dans une série de 60 méningiomes. HuR (ELAV-like 1) est une protéine pro-oncogène pouvant stimuler la prolifération et la survie cellulaire. Dans la seconde partie de cette étude, nous analysons l'expression de HuR et les effets de l'inhibition de HuR sur la prolifération, l'apoptose et la résistance à l'hypoxie. Résultats : Il existe une corrélation significative entre le grade histologique et l'expression nucléaire de MCM6 (p<0,001), Ki-67 (p<0,001) et PHH3 (p<0,001), et une corrélation inverse entre ces marqueurs et la survie sans récidive (Cox ; MCM6 : p<0,001 ; Ki-67 : p=0,003 ; PHH3 : p=0,037). L'expression cytoplasmique de HuR est corrélée négativement avec la survie sans récidive (p=0,028), et positivement avec le grade (I vs II : p=0,0007), l'indice mitotique (p=0,0001), Ki-67 (p=0,0007) et MCM6 (p=0,0009). In vitro, l'inhibition de HuR (siRNA) entraîne une diminution de la croissance cellulaire (p=0,0004) et de la prolifération (Ki-67, p=0,0004), et une augmentation de l'apoptose (caspase 3 clivée, p=0,002), ces différents effets étant significativement augmentés en hypoxie. L'inhibition de HuR entraîne également une diminution de SIRT1 en normoxie (p=0,01) et en hypoxie (p=0,0006). Conclusion : MCM6 est un marqueur efficace pour identifier les méningiomes à haut risque de récidive. HuR est un marqueur de mauvais pronostic, dont l'inhibition permet de diminuer la prolifération cellulaire et d'augmenter l'apoptoseIntroduction and objectives: Meningiomas are frequent and in most of cases low grade intracranial tumors, with frequent recurrences. The first objective of this study was to evaluate the prognostic value of proliferation and cell cycle markers in a series of 60 meningiomas. HuR (ELAV-like 1) is a pro-oncogenic protein that stimulates cell proliferation and survival. In the second part of this study, the objective was to evaluate HuR expression, and the effects of HuR inhibition on proliferation, apoptosis and resistance to hypoxia. Results: We found a significant correlation between histological grade and nuclear staining for MCM6 (p<0.001), Ki-67 (p<0.001) and PHH3 (p<0.001), and an inverse correlation between these markers and reccurence free survival (Cox; MCM6: p<0.001; Ki-67: p=0.003; PHH3: p=0.037). Cytoplasm staining for HuR was significantly stronger in atypical meningiomas (grades I vs II: p=0.0007), inversely correlated with progression free survival (p=0.028), and was positively correlated with mitotic index (p=0.0001), Ki-67 (p=0.0007) and MCM6 (p=0.0009). In vitro, HuR inhibition (siRNA) led to a significant decrease of cell growth (p=0.0004) and proliferation (Ki-67, p=0.0004), and an increase of apoptosis (cleaved caspase 3, p=0.002). These effects were significantly increased under hypoxia, comparing with normoxia. When HuR was inhibited, SIRT1 was decreased, both under normoxia (p=0.01) and hypoxia (p=0.0006). Conclusion: In conclusion, MCM6 is an efficient marker to identify meningiomas with high risk of recurrence. HuR is correlated with a poor prognosis. Its inhibition allows to decrease cell proliferation and to increase apoptosisNANCY-INPL-Bib. électronique (545479901) / SudocSudocFranceF

Hormone Receptor Expression in Meningiomas: A Systematic Review

Meningiomas are, in most cases, low grade intracranial tumors. However, relapses are frequent. To date, only a few prognostic markers are described in the literature. Several studies have discussed the expression of progesterone, estrogen, androgen, and somatostatin receptors. The utility of analyzing these expressions for prognostic, theragnostic, and therapeutic purposes remains unclear. The aim of this study was to report the expression of these receptors, based on immunohistochemistry. Cochrane Collaboration guidelines and PRISMA statements were followed. We did an online search in PubMed using the MeSH database. References were selected if the investigations occurred from 1990 to 2022. 61 references were included (34 descriptive observational studies, 26 analytical observational studies, and one case report). In this review, we describe the expression of these receptors in function of age, sex, hormonal context, localization, histological subtype, grade, and recurrence

Neurotensin and Its Involvement in Reproductive Functions: An Exhaustive Review of the Literature

International audienceNeurotensin (NTS) is a peptide discovered in 1973, which has been studied in many fields and mainly in oncology for its action in tumor growth and proliferation. In this review of the literature, we wanted to focus on its involvement in reproductive functions. NTS participates in an autocrine manner in the mechanisms of ovulation via NTS receptor 3 (NTSR3), present in granulosa cells. Spermatozoa express only its receptors, whereas in the female reproductive system (endometrial and tube epithelia and granulosa cells), we find both NTS secretion and the expression of its receptors. It consistently enhances the acrosome reaction of spermatozoa in mammals in a paracrine manner via its interaction with NTSR1 and NTSR2. Furthermore, previous results on embryonic quality and development are discordant. NTS appears to be involved in the key stages of fertilization and could improve the results of in vitro fertilization, especially through its effect on the acrosomal reaction

Postmortem Hyperthermia

International audienc

A Nonradiated Grade II Glioma That Underwent Delayed Malignant Transformation to a Gliosarcoma with Meningeal Growth and Dissemination

International audienceBackground: Secondary gliosarcomas are rare tumors, especially those arising from a World Health Organization (WHO) grade II glioma not irradiated. We report a case with subtotal resection for a WHO grade II oligoastrocytoma, without adjuvant treatment, whose metaplastic transformation into gliosarcoma suddenly occurred 4 years later with meningeal dissemination. We show a favorable outcome after therapeutic management of this rare entity.Patient: A 46 year-old woman underwent surgery for a right premotor WHO grade II oligoastrocytoma discovered incidentally. Because of a subtotal resection with only 1 cc of residue, no complementary therapy was given, and the patient enjoyed a normal life for 4 years. In the meantime, the magnetic resonance images performed every 6 months showed a very low growth rate. Suddenly, the tumor switched toward a gliosarcoma profile with meningeal dissemination.Results: Reoperation, radiotherapy, and chemotherapy were performed, enabling a control of the disease with 15 months of follow-up (i.e., with radiologic shrinkage of the multiple lesions and preservation of quality of life).Conclusion: A delayed sarcomatous transformation can acutely occur with a low proliferation index in a nonirradiated WHO grade II oligoastrocytoma. Furthermore, an aggressive therapeutic strategy can allow control of secondary gliosarcomas, even in cases of leptomeningeal spreading